生命科学资讯
生物技术与制药领域的最新动态
FTC settles insulin lawsuit with Express Scripts
AbbVie says immunology blockbusters will be 'main drivers' of growth post-Humira
诺华调整早期研发管线：剔除6个项目，新增2个癌症候选药物。
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
礼来放弃Prevail收购案中三项管线药物，包括基因疗法，交易价值10亿美元。
Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
Thermo Fisher Scientific (TMO) 近期股价疲软后，其定价是否依然合理 - simplywall.st
Is Thermo Fisher Scientific (TMO) Pricing Look Reasonable After Recent Share Price Weakness - simplywall.st
罕见儿科PRV项目通过政府资助法重新授权至2029年。
Rare pediatric PRV program reauthorized until 2029 via government funding law
特朗普签署包含PBM改革、居家医院及远程医疗延期的资金法案。
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
2026年2月4日融资动态
Financings for Feb. 4, 2026
2026年2月4日诊所动态
In the clinic for Feb. 4, 2026
2026年2月4日其他值得关注的新闻
Other news to note for Feb. 4, 2026
2026年2月4日监管动态
Regulatory actions for Feb. 4, 2026
BARDA提供1亿美元奖金推动抗病毒药物研发
BARDA offers $100M in prize money for antiviral development
PharosAI与10x Genomics联手，利用AI和空间生物学革新癌症研究 - 市场观察者网
PharosAI and 10x Genomics partner to transform cancer research with AI and spatial biology - marketscreener.com
诺和诺德股价因销售前景黯淡暴跌两位数。
Novo shares tumble by double digits on grim sales outlook
礼来股价再创新高，减肥药销售火爆超华尔街预期。
Lilly soars again as fast-selling weight loss drugs top Wall Street projections
葛兰素史克新任CEO寻求20亿至40亿美元“显而易见”的交易机会。
GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
美敦力加码收购以色列医疗设备公司CathWorks，交易金额高达5.85亿美元。
Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks
FDA要求雅培就Libre检查违规问题作出更好回应。
FDA demands better response from Abbott over Libre inspection violations
临床前干细胞生物科技公司PrimeGen选择SPAC方式登陆纳斯达克。
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq